InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,131.60
(
-0.23%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.29
(
-0.21%
)
Bitcoin
61,064.82
(
0.41%
)
Post# of 3067
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

stockspirit

Send PM Follow Ignore
Followers 13
Posts 1242
Boards Moderated 0
Alias Born 12/29/2010

stockspirit

Re: None

Monday, 06/06/2016 8:47:09 AM

Monday, June 06, 2016 8:47:09 AM

Post# of 3067
I thought this statement in today's news release is very interesting.

“The development of nicotinamide riboside for Cockayne Syndrome and other pharmaceutical indications is starting to accelerate and we are currently evaluating strategic options for these undervalued pharmaceutical opportunities.”

Somethings up in the near future. JMO
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CDXC News
More CDXC News
InvestorsHub NewsWire

FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM

HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM

Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM

ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM

Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM

Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM

Start posting your company's news
Only $200 per official company press release!